Form 4: Day One Biopharma GC Granted 175,000 Equity Awards

Day One Biopharmaceuticals' General Counsel and Secretary, Adam Dubow, was granted 105,000 stock options and 70,000 Restricted Stock Units, effective January 30, 2026.

Summary

• Adam Dubow, General Counsel and Secretary of Day One Biopharmaceuticals, Inc. (DAWN), was granted 105,000 stock options and 70,000 Restricted Stock Units (RSUs).
• The stock options have an exercise price of $11.16 per share and will vest as to 1/48th of the total shares monthly, commencing February 28, 2026, subject to continued service.
• The stock options have an expiration date of January 29, 2036.
• The RSUs represent a contingent right to receive one share of Common Stock upon settlement and will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15, and November 15, subject to continued service.
• RSUs do not expire; they either vest or are canceled prior to the vesting date.
• Following these transactions, Adam Dubow beneficially owns 105,000 stock options and 70,000 Restricted Stock Units directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal for executive retention and alignment of interests, reflecting ongoing commitment to the company's long-term strategy, without indicating any immediate operational or financial changes.

Positives

• The equity grants align the General Counsel's long-term interests with those of the shareholders, promoting sustained commitment to the company's success.
• The grants serve as a retention mechanism for a key executive, ensuring continuity in leadership and legal oversight.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants are a standard component of executive compensation in the biotechnology industry, aligning management incentives with long-term shareholder value creation and promoting executive retention.

Comparison to Industry Standards

• Equity grants, including stock options and Restricted Stock Units, are a common compensation practice across various industries, particularly in high-growth sectors like biotechnology, to attract, motivate, and retain key talent.
• The specific size and vesting schedule of these grants would typically be benchmarked against similar roles and company stages within the biopharmaceutical sector, though such comparative data is not provided in this filing.

Related Party Transactions

• Equity grants (105,000 stock options and 70,000 Restricted Stock Units) to Adam Dubow, General Counsel & Secretary, as part of his compensation package.

Stakeholder Impact

• Shareholders: Interests are further aligned with management through long-term equity incentives, potentially leading to better long-term performance.
• Employees (specifically Adam Dubow): Receives significant equity compensation, enhancing retention and motivation.

Next Steps

• Continued vesting of the granted stock options and Restricted Stock Units over their respective schedules, subject to Adam Dubow's continued service to the company.

Key Dates

Recommendation

The equity grants to a key executive are a routine compensation event that aligns management's long-term interests with shareholders. This filing does not provide new fundamental information that would significantly alter an existing investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Day One Biopharmaceuticals, DAWN, SEC Form 4, Stock Option, Restricted Stock Units, Equity Grant, Executive Compensation, Adam Dubow, General Counsel, Insider Transaction